Why Wegovy (Semaglutide 2.4 mg) Causes Sulfur Burps: The Mechanism Explained

What the Wegovy label records

Wegovy is semaglutide, a once-weekly GLP-1 receptor agonist approved for weight management, cardiovascular risk reduction and MASH [1]. In the label's pooled safety data from three placebo-controlled trials, 2,116 adults on 2.4 mg weekly and 1,261 on placebo treated for up to 68 weeks, eructation was reported by 7% of people on Wegovy and by fewer than 1% on placebo [1]. Eructation also appears in the label's list of the most common adverse reactions, those seen in 5% or more of patients [1].

How burping compares with the other gut effects

Burping is one of the less frequent gastrointestinal complaints in that same table. Nausea was reported by 44% versus 16% on placebo, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, abdominal pain 20% versus 10%, and dyspepsia 9% versus 3% [1]. Any gastrointestinal reaction was reported by 73% versus 47% [1].

Treatment was stopped for adverse reactions by 6.8% versus 3.2%; the most common adverse reactions leading people to stop Wegovy were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%) and diarrhea (0.7% versus 0.1%) [1]. The label's discontinuation figures name nausea, vomiting and diarrhea, not burping [1].

What is documented about the stomach

The label states that semaglutide delays gastric emptying, and its drug interactions section says this delay may affect the absorption of oral medicines, with closer clinical or laboratory monitoring suggested for drugs with a narrow therapeutic index [1]. The label reports the delayed emptying and the burping separately and does not say how, or whether, one leads to the other [1].

What the label says to watch for

The label instructs prescribers to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain sometimes radiating to the back, with or without nausea or vomiting, and to discontinue Wegovy if pancreatitis is suspected [1]. It warns that gastrointestinal reactions can be severe, states that Wegovy is not recommended in patients with severe gastroparesis, and lists postmarketing reports of ileus, intestinal obstruction and severe constipation with fecal impaction [1]. The label does not state that semaglutide causes gastroparesis [1].

Does the label say when burping happens?

No. Wegovy starts at 0.25 mg weekly for 4 weeks, then steps to 0.5 mg, 1 mg and 1.7 mg in 4-week blocks, reaching maintenance from week 17 [1]. The recommended adult maintenance dose is 2.4 mg, and adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. The 7% figure covers the whole treatment period of those trials rather than a particular week of titration, so the label does not show whether burping clusters around dose increases [1].